Edge Capital Group LLC Acquires 64 Shares of Zoetis Inc. (NYSE:ZTS)

Edge Capital Group LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,786 shares of the company’s stock after purchasing an additional 64 shares during the period. Edge Capital Group LLC’s holdings in Zoetis were worth $310,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Asset Dedication LLC raised its stake in Zoetis by 4.8% during the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after buying an additional 54 shares during the last quarter. Angeles Wealth Management LLC raised its position in shares of Zoetis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after purchasing an additional 56 shares during the last quarter. Forza Wealth Management LLC raised its position in shares of Zoetis by 1.8% in the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock worth $574,000 after purchasing an additional 58 shares during the last quarter. L. Roy Papp & Associates LLP boosted its stake in Zoetis by 2.8% in the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock worth $385,000 after purchasing an additional 60 shares in the last quarter. Finally, Stokes Family Office LLC grew its position in Zoetis by 1.7% during the 2nd quarter. Stokes Family Office LLC now owns 3,826 shares of the company’s stock valued at $663,000 after purchasing an additional 65 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

NYSE ZTS opened at $192.64 on Monday. The stock has a market capitalization of $87.90 billion, a price-to-earnings ratio of 37.12, a PEG ratio of 2.98 and a beta of 0.88. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The business’s fifty day moving average price is $184.70 and its 200-day moving average price is $174.33.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.41 earnings per share. On average, equities analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent analyst reports. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.